These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38906740)

  • 1. Dismantling relapsed/refractory mantle cell lymphoma.
    Ryan CE; Kumar A
    Blood Rev; 2024 Sep; 67():101221. PubMed ID: 38906740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of relapsed/refractory mantle cell lymphoma.
    Alzahrani M; Villa D
    Leuk Lymphoma; 2024 Aug; 65(8):1044-1054. PubMed ID: 38635491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic options for relapsed/refractory mantle cell lymphoma.
    Eyre TA; Cheah CY; Wang ML
    Blood; 2022 Feb; 139(5):666-677. PubMed ID: 34679161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
    Owen C; Berinstein NL; Christofides A; Sehn LH
    Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging therapies in mantle cell lymphoma.
    Hanel W; Epperla N
    J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
    Wang JF; Wang Y
    Expert Rev Hematol; 2024 Oct; 17(10):651-659. PubMed ID: 39109468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
    Bond DA; Alinari L; Maddocks K
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
    Yamshon S; Martin P
    Clin Adv Hematol Oncol; 2021 Jun; 19(6):376-382. PubMed ID: 34106911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
    Rule S; Chen RW
    Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.
    Munoz JL; Wang Y; Jain P; Wang M
    Curr Oncol Rep; 2022 Oct; 24(10):1299-1311. PubMed ID: 35596920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequencing of Novel Therapies for Mantle Cell Lymphoma.
    Romancik JT; Cohen JB
    Curr Treat Options Oncol; 2021 Nov; 22(12):118. PubMed ID: 34812968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.
    Klener P
    Expert Opin Ther Targets; 2020 Oct; 24(10):1029-1045. PubMed ID: 32842810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
    Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
    Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Update on treatment strategies for mantle cell lymphoma].
    Fukuhara S
    Rinsho Ketsueki; 2024; 65(9):1012-1018. PubMed ID: 39358255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults.
    De SK
    Curr Med Chem; 2024; 31(30):4757-4762. PubMed ID: 37818564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma.
    Morabito F; Recchia AG; Vigna E; Botta C; Skafi M; Abu-Rayyan M; Atrash M; Galimberti S; Morabito L; Al-Janazreh H; Martino M; Cutrona G; Gentile M
    Expert Opin Pharmacother; 2020 Jan; 21(1):29-38. PubMed ID: 31738609
    [No Abstract]   [Full Text] [Related]  

  • 18. New Directions for Mantle Cell Lymphoma in 2022.
    Kumar A; Eyre TA; Lewis KL; Thompson MC; Cheah CY
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35561299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapies for relapsed/refractory mantle cell lymphoma.
    Arora PC; Portell CA
    Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
    McCulloch R; Eyre TA; Rule S
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):923-939. PubMed ID: 32861287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.